59 results about "Healed myocardial infarct" patented technology

The invention belongs to the technical field of medicines, and relates to a traditional Chinese medicine composition and particularly relates to a traditional Chinese medicine composition for treating myocardial infarction and an application of the traditional Chinese medicine composition in preparation of medicines for preventing or treating myocardial infarction. Aiming at the problem that current chemical therapeutic for myocardial infarction is greater in hepatotoxicity, the invention provides the traditional Chinese medicine composition for treating or preventing myocardial infarction. The composition comprises the following components in parts by weight: 15 parts of gallnuts, 6 parts of honeysuckle, 10 parts of eucommia ulmoides, 10 parts of circium japonicum, 10 parts of ligusticum wallichii, 20 parts of radix rehmanniae, 20 parts of periostracum cicada, 10 parts of poria cocos, 5 parts of radix paeoniae alba, 5 parts of codonopsis pilosula and 10 parts of liquorice. The traditional Chinese medicine composition has a very good curative effect in the aspect of treating myocardial infarction and has a remarkable clinical promotional value.

The invention relates to application of E1A-simulated gene cellular repressor (CREG) protein, in particular to application of CREG protein or active fragment thereof in preparation of drug used for preventing and/or treating acute myocardial infarction, heart failure after acute myocardial infarction and/or ventricular remodeling after the same. The invention further relates to application of recombinant vector or recombinant cell expressing the CREG protein or the active fragment thereof in preparation of the drug used for preventing and/or treating acute myocardial infarction, heart failure after acute myocardial infarction and/or ventricular remodeling after the same.

The invention belongs to the field of traditional Chinese medicine and relates to a traditional Chinese medicine composition for treating myocardial infarction and a preparation method thereof. The traditional Chinese medicine composition is mainly prepared from, by weight, 20-30 parts of Vitex, 18-26 parts of Rhizoma corydalis, 20-28 parts of Flos carthami, 16-24 parts of Curcuma zedoary, 14-20 parts of Salvia miltiorrhiza, 14-22 parts of Caulis polygoni multiflori, 12-16 parts of Folium ginkgo bilobae, 10-18 parts of leaf of Moringa oleifera, 8-12 parts of Allium macrostemon, 6-10 parts of Mangnolia officinalis, 6-12 parts of Radix aconiti carmichaeli, 10-16 parts of Costus root, 8-16 parts of Herba taxilli and 8-18 parts of Radix glycyrrhiza. The traditional Chinese medicine composition has efficacy of activating blood to dredge collaterals, dispersing stasis to stop pain and activating blood to nourishing heart, has remarkable effect on treating myocardial infarction and is high in clinical popularization and application value.

The invention relates to a natural medicine composition used for treating cardiovascular diseases. The natural medicine composition comprises aconitine, liquiritin and 6-gingerol and is prepared into oral preparations, such as hard capsules, soft capsules, tablets, granules, powder, pills, tea bags and medicinal liquor by utilizing synergistic effects of the components. The composition can achieve the effects of treating rats with heart failures caused by myocardial infarction, increasing the ejection fractions and fractional shortening of the rats, obviously improving cardiomyocyte morphologies, reducing the degree of cardiac collagen fibrosis and reducing the contents of aldosterone and atrial natriuretic peptide in serums, and has the function of treating cardiovascular diseases. The composition has definite pharmacodynamic effects, is rigorous in quality control and small in taking dosage and is convenient to take.

The invention provides a human adipose mesenchymal stem cell exosome with high expression of IL-10 for treating myocardial infarction and use of the exosome, and relates to the technical field of biology. The invention provides the human adipose mesenchymal stem cell exosome with high IL-10 expression for treating myocardial infarction. The human adipose mesenchymal stem cell exosome is secreted by human adipose mesenchymal stem cells with over-expression of IL-10. According to the present invention, the human adipose mesenchymal stem cell exosome has the advantages that the human adipose mesenchymal stem cell exosome with over-expression of IL-10 is prepared by culturing the human adipose mesenchymal stem cells with over-expression of IL-10, and the human adipose mesenchymal stem cell exosome with over-expression of IL-10 contains a large amount of IL-10 and other various RNAs and cell factors, so that infarcted myocardial cells are effectively repaired, the heart function is enhanced, the compensatory myocardial load is reduced, and the heart failure is relieved; and a treatment medicine or a treatment strategy is provided for myocardial infarction.

The invention discloses an application of multi-type mixed cells in myocardial infarction cell treatment, wherein the multi-type mixed cells are cells derived from vein bridge vessels after a vein istransplanted to an artery. The invention also provides the application of the multi-type mixed cells as a medicament for preventing or treating myocardial infarction. When the multi-type mixed cell disclosed by the invention is applied to myocardial infarction treatment, the cardiac function after myocardial infarction can be improved, the left ventricular ejection fraction can be increased, the infarct area and the wall thickness can be reduced, and the inner diameter of the ventricle can be reduced, so that symptoms can be improved, and the application has important clinical significance.

The invention provides a method for preparing a myocardial patch. The method includes the steps: (1) preparing myocardial patch materials; (2) controlling uniform arrangement of cells in the patch materials by dielectrophoresis. The cells are controlled by the dielectrophoresis and uniformly distributed in the myocardial patch materials, and the proliferation efficiency of the cells in the materials is improved. Besides, cell arrangement on the patch materials can be adjusted according to characters of a myocardial infarction portion, the myocardial infarction portion can be completely coveredby the smaller patch, and myocardial infarction can be more effectively treated. The industrially applicable myocardial patch with excellent performances and capable of more effectively reactivatingthe myocardial infarction portion is provided for the prior art, and the myocardial patch has good market prospects and social benefit values.

The invention discloses a nilotinib-loaded heart microneedle patch for targeted myocardial administration and myocardial fibrosis treatment, and a preparation method of the nilotinib-loaded heart microneedle patch. According to the method, GelMA hydrogel with natural biocompatibility and biodegradability is used for loading an anti-fibrosis drug nilotinib; a drug-loaded microneedle patch is prepared through ultraviolet light cross-linking curing; the microneedle patch naturally forms a radian attached to the surface of the heart in the curing process, has good mechanical properties and drug release performance, is attached to the surface of an epicardium, not only can release drugs in a targeted myocardial manner and exert the drug effect at a safe dosage, but also can provide mechanical support for the heart, prevent cardiac rupture, prevent left ventricular remodeling after myocardial infarction, and improve cardiac functions; and the drug-loaded heart microneedle patch has pharmacological and mechanical treatment effects at the same time, has good prospects for treating excessive cardiac fibrosis after myocardial infarction, preventing ventricular remodeling and improving cardiac functions, and has the advantages of high targeting property and high safety.

The invention relates to a manufacturing method and application of a rat myocardial infarction model. The method comprises the steps of anesthesia, intubation, connection with a breathing machine to assist breathing, caudal vein blood drawing, solidification, breaking into tiny thrombus, layer-by-layer thoracotomy of intercostal space, injection of thrombus into a left trunk in the coronary artery direction, and observation of the electrocardiogram condition of a rat. Accurate embolism is caused by using autologous thrombus, target blood vessels can be embolized more accurately, the autologous thrombus can better reflect the pathophysiological state of model I-type myocardial infarction and has no rejection reaction, and a local coronary artery injection technology is far smaller in injury than ligation, more accurate in effect and lower in death rate. The method can be applied to medicines for evaluating and treating myocardial infarction and treatment methods for evaluating and treating myocardial infarction.

The present invention relates to the field of myocardial infraction (MI). It more specifically relates to an agent stimulating, either directly or indirectly, the 5-hydroxytryptamine 1B receptor, and to a composition comprising said agent, for use in the treatment of a patient having a myocardial infraction (MI). The invention further encompasses therapeutic and screening methods.

The invention discloses application of agrimonolide in antagonizing myocardial cell injury caused by hypoxia. The research results show that agrimonolide can protect myocardial cells damaged by hypoxia through promoting myocardial cell proliferation, inhibiting apoptosis caused by anoxia, maintaining the integrity of cell morphology and enhancing the function of mitochondria, and theoretical support is provided for development of new drugs for treating myocardial infarction.

The invention provides a preparation method of human adipose tissue-derived stromal cell exosome with high expression of IL-10 for treating myocardial infarction, and relates to the technical field ofbiology. The preparation method comprises the following steps: culturing human adipose tissue-derived stromal cells over-expressing IL-10, and collecting a cell culture solution; and carrying out differential centrifugation on the cell culture solution, collecting the supernatant, carrying out ultracentrifugation on the supernatant to obtain target microspheres, and filtering, purifying and sterilizing the target microspheres to obtain the exosome. The preparation method has the advantage that by culturing human adipose tissue-derived stromal cells over-expressing IL-10, the human adipose tissue-derived stromal cell exosome capable of over-expressing IL-10 is prepared; the IL-10 overexpression human adipose tissue-derived stromal cell exosome contains a large amount of IL-10 and other various RNAs and cytokines, effectively repairs infarcted myocardial cells, enhances the cardiac function, reduces compensatory myocardial load, relieves heart failure, and provides a therapeutic drug ora therapeutic strategy for myocardial infarction.

The invention discloses a collagen composite bioactive stent and a preparation method thereof. The collagen composite bioactive stent is prepared through the steps that I-type rat tail collagen is dissolved in an acetic acid solution, a DME/F12 culture medium and a NaOH solution are added to prepare an I-type rat tail collagen solution, CSCI and beta-sodium glycerophosphate are dissolved in the DME/F12 culture medium to prepare a temperature-sensitive CSCI solution, and the I-type rat tail collagen solution is mixed with the temperature-sensitive CSCI solution. The collagen composite bioactivestent can be used for treating myocardial infarction ischemic heart diseases by being taken as tissue engineered myocardium to be injected into a myocardial ischemia area.

The invention discloses a heart microneedle patch loaded with a TGF-beta inhibitor Galunsertib, and a preparation method of the heart microneedle patch. According to the method, natural polymer hydrogel GelMA and an anti-fibrosis drug TGF-beta inhibitor Galunsertib are premixed according to a certain proportion; a drug-loaded microneedle patch is prepared through ultraviolet light cross-linking curing; the microneedle patch has good mechanical properties and drug release performance and is attached to the surface of an epicardium after myocardial infarction; a microneedle array can absorb interstitial fluid to swell and degrade, target myocardial release drugs and inhibit myocardial fibrosis; furthermore, mechanical support is provided for a heart by forming a membrane structure system with certain strength, so that heart rupture is prevented; and the drug-loaded heart microneedle patch has pharmacological and mechanical treatment effects at the same time, has good prospects for treating excessive cardiac fibrosis after myocardial infarction, preventing ventricular remodeling and improving cardiac functions, and has the advantages of high targeting property and high safety.

The invention discloses a left ventricle geometric model construction method and device for injectable hydrogel curative effect evaluation, and belongs to the field of image processing. The method comprises the following steps: acquiring a magnetic resonance image comprising a left ventricle; segmenting the magnetic resonance image to obtain different organ tissue sets of the left ventricle; for each pixel, constructing a three-variable quadratic polynomial volume function block on a 3*3*3 image block taking the pixel as the center; on each unit cube formed by eight adjacent pixels, weightingand averaging the quadratic polynomial volume function blocks of all the pixels in the cube, and constructing a three-variable cubic polynomial volume function block; and combining all cubic polynomial volume function blocks together to obtain a left ventricle three-dimensional geometric model. The method for constructing the high-precision left ventricular solid model is provided for evaluating the curative effect of the hydrogel on myocardial infarction treatment, an effective technology is provided for high-accuracy evaluation, and an important auxiliary technology is provided for medical staff to improve the curative effect on myocardial infarction treatment.

The invention discloses a mixed cell preparation used for treating myocardial infarction as well as a preparation method thereof and an application thereof. The mixed cell preparation consists of active ingredients and a solvent, wherein the active ingredients are mainly CTs and CSCs. The mixed cell preparation is transplanted for an ischemic region and an ischemic penumbra region of a heart with acute myocardial infarction, so that survival, differentiation and multiplication, on the ischemic penumbra region, of transplanted CSCs or myocardial endogenous CSCs and other derived stem cells can be effectively promoted, and a severely damaged cell network which consists of CTs of a regenerative ischemic myocardium ischemic region is effectively repaired, and therefore, regeneration of infarcted myocardium is facilitated. The mixed cell preparation has curative effect, which is superior to that of independent use of CSCs, BMSCs and CTs, in reducing an infarct size and improving the function of a myocardial infarction heart, and the like after implementing transplantation therapy on acute myocardial infarction. Therefore, the mixed cell preparation can be prepared into a drug for treating myocardial infarction or applied to mechanical apparatuses and instruments.

The invention discloses a biomarker for diagnosing and treating myocardial infarction. The biomarker comprises LINC00997 and/or HAUS3. The invention discloses application of a reagent for detecting the expression level of LINC00997 and/or HAUS3 genes in the preparation of a product for diagnosing myocardial infarction. The invention also discloses a method for screening candidate drugs for preventing or treating myocardial infarction.

The invention belongs to the field of medicines, and discloses application of ursolic acid derivatives to preparation of a medicine for preventing or treating cardiovascular diseases. According to the invention, ursolic acid is successfully subjected to structural modification by utilizing a microbial conversion technology, four novel compounds with parent nucleus structure modification are obtained, and in-vitro myocardial cell injury protection tests and myocardial cell ischemia reperfusion tests prove that the compounds have a good myocardial cell protection activity, can be used as active ingredients of medicines for treating the myocardial infarction, the coronary atherosclerotic heart disease and the chronic heart failure, and has wide application.